United States Patent 10,028,963: Ceftolozane-Tazobactam Pneumonia Patent Scope and Landscape

US Patent No. 10,028,963 protects a dosing method for ceftolozane-tazobactam in pneumonia. The independent claim requires intravenous administration of 2.0 g of ceftolozane, with tazobactam, approximately every eight hours. The dependent claims narrow the method to a 60-minute infusion, specified ceftolozane salt or free-base forms, nosocomial, ventilator-acquired or hospital-acquired pneumonia, and infections involving Pseudomonas aeruginosa, E. coli or Klebsiella pneumoniae.

The patent is directed to use of the product marketed as Zerbaxa, not to a broad ceftolozane compound monopoly. Its commercial significance is concentrated in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia dosing.

What does US Patent 10,028,963 cover?

US 10,028,963 covers a treatment regimen with five core elements:

Claim element	Requirement
Disease	Pneumonia
Active antibacterial	2.0 g ceftolozane
Combination agent	Tazobactam must be present in the pharmaceutical composition
Route	Intravenous administration
Frequency	Repeated administration about once every eight hours

Claim 1 is the controlling independent claim. A competing product or treatment protocol must satisfy every limitation of the claim for literal infringement.

The claim does not expressly require:

A specified tazobactam dose;
A 2:1 ceftolozane-to-tazobactam ratio;
A 60-minute infusion;
A particular ceftolozane salt;
A named pathogen;
Nosocomial, hospital-acquired or ventilator-acquired pneumonia.

Those restrictions appear in dependent claims. A regimen that satisfies claim 1 can infringe without satisfying any dependent claim.

What is the commercial regimen covered by the patent?

The FDA-approved adult dose of Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia is 3 g, consisting of 2 g ceftolozane and 1 g tazobactam, administered intravenously every eight hours over one hour. Treatment duration is generally 8 to 14 days, subject to the clinical circumstances and renal function.[1]

That labeled regimen maps directly onto claim 1 and claim 2:

2 g ceftolozane;
tazobactam in the same composition;
intravenous delivery;
every eight hours;
60-minute infusion.

The claims therefore cover the principal labeled pneumonia regimen rather than an off-label dosing variation.

How do claims 1 through 11 differ?

Claim	Scope
1	Broadest claim: repeated IV administration of 2 g ceftolozane with tazobactam approximately every eight hours for pneumonia
2	Claim 1 plus a 60-minute infusion
3	Claim 1 plus ceftolozane in salt form
4	Claim 3 plus the hydrogen sulfate salt
5	Claim 1 plus ceftolozane in free-base form
6	Claim 1 limited to nosocomial pneumonia
7	Claim 1 limited to ventilator-acquired pneumonia
8	Claim 1 limited to hospital-acquired pneumonia
9	Claim 6 plus ceftolozane free base
10	Claim 6 plus ceftolozane salt form
11	Claim 1 limited to infection involving P. aeruginosa, E. coli or K. pneumoniae

Claims 6, 7 and 8 are clinically important because they correspond to the hospital-acquired and ventilator-associated pneumonia indications added to the Zerbaxa label in 2019.[1] Claim 11 is broader than a single-pathogen claim because it covers an infection involving one or more of the listed organisms.

What is the claim scope for salt and free-base ceftolozane?

The patent captures both salt and free-base administration through separate dependent claims.

Claim 4 specifically recites the hydrogen sulfate salt. Claim 5 separately covers the free-base form. Claims 9 and 10 apply the same distinction within the nosocomial-pneumonia subset.

This drafting reduces the ability of a potential entrant to avoid the patent by changing the chemical presentation of ceftolozane. A product using a different salt would not automatically fall within claim 4, but it could still fall within claim 1 or claim 3 if the remaining limitations are met. The patent's strongest chemical-form protection is therefore concentrated in claims 3, 4, 5, 9 and 10, while the principal commercial risk remains claim 1.

What patent protects the Zerbaxa product and how does US 10,028,963 fit?

Zerbaxa has a layered patent estate. The relevant layers include:

Protection layer	Typical subject matter	Relevance to US 10,028,963
Active pharmaceutical ingredient	Ceftolozane and related chemical forms	Separate from the claimed treatment method
Combination product	Ceftolozane with tazobactam	Supports the marketed combination but is not the central subject of the asserted claims
Formulation	Injectable pharmaceutical compositions and stability characteristics	Can create separate infringement exposure
Method of treatment	Dosing ceftolozane-tazobactam for specified infections	Primary subject of US 10,028,963
Indication-specific use	Hospital-acquired and ventilator-associated bacterial pneumonia	Reflected in claims 6 through 8 and the FDA label
Manufacturing	Preparation, isolation or formulation processes	May create supply-chain barriers independent of the treatment claims

US 10,028,963 is therefore a use patent within the broader Zerbaxa estate. It does not, on the face of the supplied claims, prevent every manufacture or sale of ceftolozane-tazobactam. Its practical effect is strongest where a generic or follow-on product is promoted for the patented pneumonia regimen.

When does US Patent 10,028,963 expire?

The patent issued on July 24, 2018. Public patent records identify an August 6, 2033 patent-term endpoint associated with the relevant family, subject to any applicable patent-term adjustment, disclaimer or other USPTO adjustment reflected in the official record.[2]

The key commercial timeline is:

Event	Date
Earliest identified priority date	August 6, 2012
Patent issuance	July 24, 2018
FDA approval of Zerbaxa for cIAI and cUTI	December 19, 2014
FDA approval of the HABP/VABP indication	June 3, 2019
Expected family-based expiration	August 6, 2033

The FDA's Orange Book should control the operative listed expiration date for abbreviated new drug application analysis. Patent term adjustment and any terminal disclaimer can change the date displayed in USPTO or FDA records.[3]

What is the Orange Book status of US 10,028,963?

US 10,028,963 is associated with the Zerbaxa regulatory product, NDA 206829, and is relevant to the approved hospital-acquired and ventilator-associated pneumonia uses.[3] Its importance in an ANDA analysis depends on:

Whether the patent remains listed for the relevant NDA;
The use code submitted by the NDA holder;
Whether an ANDA applicant seeks approval for the same indication;
Whether the applicant files a Paragraph IV certification or a section viii statement;
Whether the FDA accepts a carve-out that removes the patented use from the proposed labeling.

The patent covers a method of treatment, so a generic applicant may attempt a section viii labeling carve-out for the patented pneumonia indication while seeking approval for other approved uses, such as complicated intra-abdominal infection or complicated urinary tract infection. That strategy becomes more difficult if the proposed label retains hospital-acquired or ventilator-associated pneumonia language.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could challenge US 10,028,963 through a Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed. The principal legal attack vectors would include:

Anticipation and obviousness

The challenger would examine prior disclosures of:

Ceftolozane-tazobactam in pneumonia;
2 g ceftolozane dosing;
Every-eight-hour administration;
One-hour infusion;
Activity against P. aeruginosa and Enterobacterales;
The safety and pharmacokinetic rationale for the regimen.

The strongest invalidity question is likely obviousness. The individual elements are clinically conventional in isolation, but the patent holder would argue that the specific regimen, pneumonia population and exposure profile produced an unexpected therapeutic result.

Written description and enablement

The claims cover pneumonia broadly in claim 1, while the dependent claims identify specific hospital pathogens and disease categories. A challenger could argue that the specification does not adequately support the full breadth of the claimed pneumonia population or every covered dosing implementation.

Inducement

Even if a generic company does not administer the drug itself, labeling that instructs hospitals to use 2 g ceftolozane with tazobactam every eight hours for pneumonia could support an induced-infringement theory. Labeling is particularly important because the patented regimen is also the FDA-approved regimen for HABP and VABP.

Section viii carve-out

A carve-out is more commercially workable for a product marketed only for non-pneumonia indications. It is less workable for a product seeking the HABP/VABP indication, because the proposed labeling would likely reproduce the patented dosing instructions.

Which companies are challenging Zerbaxa exclusivity?

Publicly available sources reviewed for this analysis do not identify a final generic launch or a reported settlement that removed US 10,028,963 from the Zerbaxa patent estate. Zerbaxa is marketed by Merck following Merck's acquisition of Cubist Pharmaceuticals. The FDA-approved product remains the principal commercial ceftolozane-tazobactam product.[1,4]

The absence of a publicly reported launch does not eliminate challenge risk. A Paragraph IV notice can remain confidential between the applicant and NDA holder until litigation is filed. The relevant competitive question is whether a challenger can obtain approval with:

A full HABP/VABP label;
A carved-out non-pneumonia label;
A different dosage or infusion schedule;
A different ceftolozane salt;
A settlement-controlled launch date.

What litigation and settlement issues affect this patent?

For US 10,028,963, the material litigation issues are likely to center on claim construction and label-based infringement.

The most important construction disputes would involve:

The meaning of "about once every 8 hours";
Whether "2.0 g of ceftolozane" permits clinically equivalent dosing expressed as total product weight;
Whether tazobactam must be administered in the same composition;
The scope of "pneumonia";
The meaning of "repeatedly";
Whether an accused product's labeling induces the patented method.

A court could construe "about once every 8 hours" to cover ordinary hospital dosing variation, but the exact range would depend on the intrinsic evidence and prosecution history. A regimen administered every 12 hours would present a stronger noninfringement position than a regimen administered every 8 to 9 hours.

No publicly identified settlement terms should be assumed for this patent. If a settlement were reached, the commercially important terms would be the authorized generic provisions, launch date, indication carve-outs and restrictions on hospital-pneumonia promotion.

How strong is the patent estate for ceftolozane-tazobactam?

The estate is strongest against a generic seeking the same FDA-approved pneumonia label and the same 3 g every-eight-hour, one-hour infusion regimen.

Risk category	Assessment
Same HABP/VABP label	High
Same 2 g/1 g regimen every 8 hours	High
Same one-hour infusion	High under claim 2
Non-pneumonia indications only	Lower under this patent
Different dosing frequency	Potentially lower, subject to claim construction and other patents
Different salt form	Not necessarily effective, because claims 1 and 5 may remain relevant
Hospital use without promotional labeling	Still presents inducement and direct-use issues
Manufacturing of the active ingredient	Primarily governed by separate compound and process patents

The patent is narrower than a compound patent because it requires a particular therapeutic use and dosing pattern. It is stronger than a conventional indication-only patent because the independent claim combines disease, route, dose, frequency and combination-product limitations.

What manufacturing and geographic barriers remain?

The patent is a United States method-of-treatment patent. It does not directly establish exclusivity in Europe, Japan, China or other jurisdictions. Foreign risk depends on corresponding national patents, local prosecution outcomes and local regulatory linkage rules.

Manufacturing risk can remain after this patent expires if separate patents cover:

Ceftolozane chemical forms;
Tazobactam combinations;
Sterile injectable formulations;
Lyophilized powders;
Reconstitution methods;
Stability or impurity control;
Commercial-scale synthesis.

A generic company can face a layered freedom-to-operate analysis even if it designs around the claims of US 10,028,963.

How does US 10,028,963 compare with a compound patent?

A compound patent generally blocks making, using or selling the claimed molecule, subject to its claim language and expiration. US 10,028,963 instead targets a specific clinical use and regimen.

Issue	Compound patent	US 10,028,963
Primary subject	Molecule or chemical form	Treatment method
Need for pneumonia use	Usually no	Yes
Need for 2 g dose	Usually no	Yes
Need for IV route and q8h schedule	Usually no	Yes
Design-around potential	Often limited	Greater, if clinically and regulatorily viable
Labeling impact	Product-wide	Concentrated in patented indication
Relevance after compound expiry	May block product	Can continue to block the covered use

Key Takeaways

US 10,028,963 claims intravenous treatment of pneumonia with 2 g ceftolozane plus tazobactam approximately every eight hours.
The claims closely track the Zerbaxa HABP/VABP regimen: 3 g total drug, administered by one-hour infusion every eight hours.
Claim 1 is the central commercial claim. Claims 2 through 11 add infusion, chemical-form, disease-category and pathogen limitations.
The patent covers both free-base and selected salt-form embodiments through separate dependent claims.
The relevant patent-family expiration is associated with August 6, 2033, subject to the official USPTO and Orange Book term records.
A generic seeking the HABP/VABP indication faces substantially greater risk than one seeking only non-pneumonia indications.
A section viii carve-out may reduce risk for non-pneumonia labeling but is difficult to reconcile with an FDA-approved HABP/VABP label.
The patent is a use patent, not a complete product or compound monopoly. Separate Zerbaxa composition, formulation, compound and process patents require independent review.

FAQs

Does US 10,028,963 cover Zerbaxa for urinary tract infections?

Not based on the supplied claims. The claims require treatment of pneumonia. Zerbaxa's complicated urinary tract infection indication is outside the express scope of these claims, although separate patents may apply.

Can a generic avoid US 10,028,963 by using a different ceftolozane salt?

Not necessarily. Claim 1 does not specify the salt form, and claim 5 covers the free base. A different salt may avoid claim 4 while remaining within claim 1 or another asserted claim.

Does claim 2 require the entire 3 g Zerbaxa dose to be infused over 60 minutes?

Claim 2 requires the ceftolozane administration to be a 60-minute infusion. Because claim 1 requires tazobactam in the pharmaceutical composition, the commercial embodiment is the combined 3 g ceftolozane-tazobactam dose.

Is US 10,028,963 a patent on ceftolozane itself?

No. It is directed to a method of treating pneumonia using a specified ceftolozane-tazobactam regimen. Patent protection for the molecule, salt forms and manufacturing processes is separate.

Could a once-daily ceftolozane-tazobactam regimen avoid the patent?

A once-daily regimen would present a potential noninfringement position against the "about once every 8 hours" limitation. It would still require separate analysis of other Zerbaxa patents, FDA approval requirements and whether the alternative regimen is clinically and regulatorily supportable.

References

U.S. Food and Drug Administration. (2023). Zerbaxa (ceftolozane and tazobactam) prescribing information. Merck Sharp & Dohme LLC.
United States Patent and Trademark Office. (2018). U.S. Patent No. 10,028,963, Methods of treating pneumonia. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.
Merck & Co., Inc. (2024). Annual report.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2848012	⤷ Start Trial
China	103945842	⤷ Start Trial
Denmark	3616695	⤷ Start Trial
Eurasian Patent Organization	028342	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,028,963

Which drugs does patent 10,028,963 protect, and when does it expire?

Summary for Patent: 10,028,963